HeXun Biosciences CoROCO:6986 23 Days Payable is 29.65 as of Dec. 2025, which is 67% below its 10-year median of 89.16. GuruFocus rates ROCO:6986 with a GF Score™ of 23/100. The stock has 1 warning sign investors should review. Among 701 Biotechnology companies, HeXun Biosciences Co ranks worse than 59.2% on this metric.
The historical rank and industry rank for HeXun Biosciences Co's Days Payable or its related term are showing as below:
ROCO:6986'
s Days Payable Range Over the Past 10 Years
Min: 50.16 Med: 89.16 Max: 331.95
Current: 68.96
During the past 6 years, HeXun Biosciences Co's highest Days Payable was 331.95. The lowest was 50.16. And the median was 89.16.
ROCO:6986's Days Payable is ranked worse than 59.2% of 701
companies
in the Biotechnology industry
Industry Median: 112.84
vs ROCO:6986: 68.96
HeXun Biosciences Co's Days Payable
declined
from Sep. 2024 (87.22) to Dec. 2025 (29.65).
It may suggest that HeXun Biosciences Coaccelerated paying its suppliers.
HeXun Biosciences Co Days Payable Related Terms
HeXun Biosciences Co Days Payable Historical Data
* Premium members only.
The historical data trend for HeXun Biosciences Co's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6986 vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, HeXun Biosciences Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HeXun Biosciences Co Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, HeXun Biosciences Co's Days Payable distribution charts can be found below:
* The bar in red indicates where HeXun Biosciences Co's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
HeXun Biosciences Co's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HeXun Biosciences Co (ROCO:6986) has a Days Payable of 29.65 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on HeXun Biosciences Co and its competitors. This is 67% below median its historical median of 89.16. Over the past decade, HeXun Biosciences Co's Days Payable has ranged from 50.16 to 331.95. According to the industry distribution chart, HeXun Biosciences Co ranks #415 out of 701 companies in the Biotechnology industry, placing it in the top 59.2%.
Is HeXun Biosciences Co's Days Payable too high?
HeXun Biosciences Co's current Days Payable of 29.65 is 67% below median its 10-year median of 89.16. Over the past 10 years, this metric has ranged from a low of 50.16 to a high of 331.95. The Biotechnology industry median Days Payable is 112.84. HeXun Biosciences Co's value of 29.65 is 73.7% below this industry median. Based on the distribution chart, HeXun Biosciences Co ranks #415 out of 701 companies in the Biotechnology industry, which is below the industry midpoint. Overall, HeXun Biosciences Co has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does HeXun Biosciences Co's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, HeXun Biosciences Co ranks #415 out of 701 companies for Days Payable. This places HeXun Biosciences Co in the lower half of its industry. The industry median Days Payable is 112.84. HeXun Biosciences Co's value of 29.65 is 73.7% below this benchmark. Historically, HeXun Biosciences Co's own Days Payable has ranged from 50.16 to 331.95 over the past decade. While the company's 10-year median is 89.16 vs. the industry median of 112.84, HeXun Biosciences Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.84, based on 701 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. HeXun Biosciences Co's current Days Payable of 29.65 is 73.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on HeXun Biosciences Co and its competitors. For the Biotechnology industry, the median Days Payable is 112.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HeXun Biosciences Co's current Days Payable is 29.65, which is 67% below median its own 10-year median of 89.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HeXun Biosciences Co stock overvalued right now?
HeXun Biosciences Co (ROCO:6986) has a current Days Payable of 29.65. The current Days Payable is 29.65, which is 67% below median its 10-year median of 89.16 and 73.7% below the Biotechnology industry median of 112.84. HeXun Biosciences Co's overall GF Score™ is 23/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For HeXun Biosciences Co (ROCO:6986), the current Days Payable is 29.65 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
HeXun Biosciences Co Ltd is engaged in the research and development of cell drugs and cell derivatives. It conducts research and development jointly with medical research institutions to use stem cells to treat cardiovascular, immune-inflammatory, and neurodegenerative diseases to develop innovative cell drugs and treatment methods. The company's main business items are new drug research and development, biotechnology services, and research and development services, such as: commissioned research and development and production services for cell medicine, agency testing and development services, and biomedical consulting services, etc.
23GF Score
Get the complete analysis for ROCO:6986
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6986 has been successfully added to your 
